Advertisement
News
Advertisement

Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets

Thu, 09/23/2010 - 12:31pm
Bio-Medicine.Org

NEW YORK, Sept, 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets

http://www.reportlinker.com/p0298009/Multiple-Sclerosis-MS-Drugs-and-Biologics-Technologies-and-Global-Markets.html

The total worldwide market for MS disease-modifying therapies is expected to grow at an 8.1% compound annual growth rate (CAGR) from 2010 through 2015, with sales reaching nearly $16.7 billion by the end of 2015, from $11.3 billion in 2010.

From 2010 through 2015, the overall small molecule MS disease-modifying drug market is expected to grow rapidly. This segment is worth an estimated $3.6 billion in 2010 and is projected to increase at a 17.4% compound annual growth rate (CAGR) to reach $7.9 billion in 2015.

Biologics represent the largest class of MS disease-modifying therapies by sales and by number of approved therapies. This sector is valued at $7.8 billion in 2010 and is expected to increase at a 2.5% compound annual growth rate (CAGR) to reach a value of $8.8 billion in 2015. 

INTRODUCTIONSTUDY GOALS AND OBJECTIVES BCC's goal in conducting this study was to determine the current status of the market for disease-modifying multiple sclerosis (MS) drugs, biologics, and vaccines and to assess their growth potential over a 5-year period from 2010 through 2015.

MS is an autoimmune disease characterized by the body's own immune system attacking itself and causing spots of demyelination (plaques) in the brain and spinal cord. Symptoms of MS vary widely depending on th

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading